iloprost has been researched along with Flushing* in 2 studies
2 other study(ies) available for iloprost and Flushing
Article | Year |
---|---|
Facial colour by chromametry and iloprost plasma levels.
Topics: Epoprostenol; Face; Flushing; Humans; Iloprost; Kinetics; Skin Pigmentation | 1989 |
Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.
The plasma levels and excretion of tritium-labeled iloprost in healthy elderly male and female volunteers have been measured after i.v. infusion of 2 ng X kg-1 X min-1 for 4 h and oral administration of 0.1 and 0.48 microgram/kg. During infusion, a steady-state of labeled compounds in the plasma was not achieved. Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively. A steady-state of unchanged iloprost was reached rapidly with a peak of 81 pg/ml. Plasma levels declined biphasically with half-lives of 6 min and 31 min. Total clearance was 24 ml X min-1 X kg-1. Maximum concentrations of labeled substances after oral administration were 307 and 1,051 pg equiv/ml after 29 and 39 min, respectively. The peak of unchanged iloprost (116 pg/ml) was observed 7.5 min after an oral dose of 0.48 microgram/kg. Bioavailability was 16%. Iloprost was totally metabolized and the metabolites were mainly excreted in urine. The main biotransformation products in plasma and urine were tentatively identified by cochromatography as dinor- and tetranoriloprost and their glucuronides. ADP-induced platelet aggregation was reduced by 60% during the i.v. infusion and 15 min after oral administration of 0.48 microgram/kg. Heart rate and blood pressure were virtually unaffected. Common side-effects were facial flush, headache and nausea. Topics: Aged; Blood Pressure; Epoprostenol; Female; Flushing; Heart Rate; Humans; Iloprost; Male; Middle Aged; Platelet Aggregation; Platelet Count; Structure-Activity Relationship; Tritium; Vasodilation | 1987 |